Literature DB >> 27600687

The neuroprotective effects of orthosteric agonists of group II and III mGluRs in primary neuronal cell cultures are dependent on developmental stage.

D Jantas1, A Gręda2, S Gołda3, M Korostyński3, W Lasoń2.   

Abstract

Activation of metabotropic glutamate receptors (mGluRs) modulates neuronal excitability. Here, we evaluated the neuroprotective potential of four structurally diverse activators of group II and III mGluRs: an orthosteric agonist of group II (LY354740), an orthosteric agonist of group III (ACPT-I), an allosteric agonist of mGluR7 (AMN082) and a positive allosteric modulator (PAM) of mGluR4 (VU0361737). Neurotoxicity was induced by the pro-apoptotic agents: staurosporine (St) and doxorubicin (Dox) or the excitotoxic factor glutamate (Glu). The effects were analyzed in primary hippocampal (HIP) and cerebellar granule cell (CGC) cultures at two developmental stages, at 7 and 12 days in vitro (DIV). The data reveal a general neuroprotective effect of group II and III mGluR activators against the St- and Glu- but not Dox-induced cell damage. We found that neuroprotective effects of group II and III mGluR orthosteric agonists (LY354740 and ACPT-I) were higher at 12 DIV when compared to 7 DIV cells. In contrast, the efficiency of allosteric mGluR agents (AMN082 and VU0361737) did not differ between 7 and 12 DIV in both, St and Glu models of neuronal cell damage. Interestingly, the protective effects of activators of group II and III mGluRs were blocked by relevant antagonists only against Glu-induced neurotoxicity. Moreover, the observed neuroprotective action of group II and III mGluR activators in the St model was associated with a decreased number of PI-positive cells and no alterations in the caspase-3 activity. Finally, we showed that MAPK/ERK pathway activation was potentially involved in the mechanism of ACPT-I- and AMN082-induced neuroprotection against the St-evoked cellular damage. Our comparative study demonstrated the developmental stage-dependent neuroprotective effect of orthosteric group II and III mGluR agonists. In comparison to allosteric modulators, orthosteric compounds may provide more specific tools for suppression of neuronal cell loss associated with various chronic neurodegenerative conditions. Our results also suggest that the inhibition of intracellular pathways mediating necrotic, rather than apoptotic cascades, may be involved in neuroprotective effects of activators of group II and III mGluRs.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ACPT-I; AMN082; Doxorubicin; Glutamate; LY354740; Primary neuronal cell cultures; Staurosporine; VU0361737

Mesh:

Substances:

Year:  2016        PMID: 27600687     DOI: 10.1016/j.neuropharm.2016.09.003

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  TNF-α Mediates the Intrinsic and Extrinsic Pathway in Propofol-Induced Neuronal Apoptosis Via PI3K/Akt Signaling Pathway in Rat Prefrontal Cortical Neurons.

Authors:  Xiaoyuan Deng; Bo Chen; Bin Wang; Junfang Zhang; Hongliang Liu
Journal:  Neurotox Res       Date:  2017-05-24       Impact factor: 3.911

Review 2.  Metabotropic glutamate receptors: targets for neuroprotective therapies in Parkinson disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  Curr Opin Pharmacol       Date:  2018-03-30       Impact factor: 5.547

3.  Neuronal metabotropic glutamate receptor 8 protects against neurodegeneration in CNS inflammation.

Authors:  Marcel S Woo; Friederike Ufer; Nicola Rothammer; Giovanni Di Liberto; Lars Binkle; Undine Haferkamp; Jana K Sonner; Jan Broder Engler; Sönke Hornig; Simone Bauer; Ingrid Wagner; Kristof Egervari; Jacob Raber; Robert M Duvoisin; Ole Pless; Doron Merkler; Manuel A Friese
Journal:  J Exp Med       Date:  2021-05-03       Impact factor: 14.307

4.  The neuroprotective effects of AMN082 on neuronal apoptosis in rats after traumatic brain injury.

Authors:  Chung-Che Lu; Tee-Tau Eric Nyam; Jinn-Rung Kuo; Yao-Lin Lee; Chung-Ching Chio; Che-Chuan Wang
Journal:  BMC Neurosci       Date:  2021-06-25       Impact factor: 3.288

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.